Brief: Lisata Therapeutics Announces Completion Of Enrollment In Phase 2B Ascend Trial Of Lsta1
12/12/2023 13:33
Dec 12 (Reuters) - Lisata Therapeutics Inc LSTA.O :
* LISATA THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN
PHASE
2B ASCEND TRIAL OF LSTA1 IN METASTATIC PANCREATIC DUCTAL
ADENOCARCINOMA
* LISATA THERAPEUTICS INC - TOP-LINE PLACEBO-CONTROLLED,
BLINDED,
RANDOMIZED DATA NOW EXPECTED IN Q4 OF 2024
* LISATA THERAPEUTICS INC - EXPECTS COMPLETE DATA SET OF
ALL 155
PATIENTS FROM STUDY BY MID-2025.
Source text for Eikon: ID:nGNX4wsMDF
Further company coverage: LSTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics - Amends Merger Offer Price To $4 Per Share Plus CVR
Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Lisata jumps as Kuva Labs strikes acquisition deal